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Purpose of the study
The purpose of the study was to evaluate patient GI toler-
ability and perceived Tx satisfaction after switching from
LPV/r SGC to LPV/r tablets.
Methods
Adult patients under LPV/r SGC Tx for at least 6 months,
and with >95% adherence, were included. Following data
were collected: overall GI side-effects; presence and grada-
tion of diarrhea according to WHO severity scale; antidi-
arrheal drugs administration during the last month under
LPV/r SGC Tx, and during 2nd and 6th month after
switching to LPV/r tablets. Also, patient Tx satisfaction
grade and preferences data were gathered.
Summary of results
Forty patients (28 male), mean age 39.9 ± 5.6 years, were
evaluated. Two patients withdrew from the study: one due
to grade 4 diarrhea and the other due to hair loss. GI
effects such abdominal pain, flatulence and nausea were
mild grade. However, during the last month under SGC
Tx, 16 (40%) patients did not suffer diarrhea; and 24 did
show diarrhea, of them 14 (35%) individuals suffered
grade 1, eight (22.5%) grade 2 and one (2.5%) grade 4.
During the 2nd month under LPV/r tablets Tx, diarrhea
disappeared or decreased in intensity in 75% of patients.
During 6th month under tablet Tx, 28 patients (70%) did
not have diarrhea. From the 12 remaining patients (30%)
with diarrhea at month 6, nine (22.5%) had grade 1, two
(5%) grade 2, and one (2.5%) grade 4. During the last
month of LPV/r SGC Tx, five patients were taking antidi-
arrheal drugs in contrast to only one patient during the
6th month under tablet Tx. 83% of the individuals
answered the Tx satisfaction questionnaire: 98% of them
referred to be Extremely satisfied, Very satisfied or Satis-
fied switching from LPV/r SGC to LPV/r tablets; 89% of
patient preferred LPV/r tablets and 11% liked both
equally.
Conclusion
New co-formulated LPV/r formulation (tablets) has been
well appreciated and tolerated by our patients, with a con-
siderable decrease in GI effects, especially in the drug-
related diarrhea severity.
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